The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Abstract
Purpose: To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. Methods: ASCO/CAP convened an Update Committee that included coauthors of the 2007 guideline to conduct a systematic literature review and update recommendations for optimal HER2 testing. Results: The Update Committee identified criteria and areas requiring clarification to improve the accuracy of HER2 testing by immunohistochemistry (IHC) or in situ hybridization (ISH). The guideline was reviewed and approved by both organizations. Recommendations: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive). Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to > 10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH). Repeat testing should be considered if results seem discordant with other histopathologic findings. Laboratories should demonstrate high concordance with a validated HER2 test on a sufficiently large and representative set of specimens. Testing must be performed in a laboratory accredited by CAP or another accrediting entity. The Update Committee urges providers and health systems to cooperate to ensure the highest quality testing. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the College of American Pathologists and has been published jointly by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine. Copyright © 2013 American Society of Clinical Oncology and College of American Pathologists. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by American Society of Clinical Oncology or College of American Pathologists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab had previously been shown to improve progression-free survival and overall survival when combined with chemotherapy in the metastatic setting.(28) Since 2005, several of the first-generation adjuvant trials have been updated and have confirmed the disease-free and overall survival benefit offered by 1 year…”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Unequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationSmith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
Self-citationCuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Self-citationPerez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Self-citationTeutsch, S. M., Bradley, L. A., Palomaki, G. E., Haddow, J. E., Piper, M., Calonge, N., Dotson, W. D., Douglas, M. P., & Berg, A. O. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e318184137c · Cited by 680
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Self-citationRomond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 438
Self-citationHER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Self-citationNiikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Self-citationMittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1735 · Cited by 330 · cited 1×
“Testing is now recommended for primary, recurrent, and metastatic tumors.(19,35,45,54-63,64) Tissue from the primary tumor can be obtained through a core needle biopsy, as well as from an incisional and excisional surgical procedure.”
BackgroundHanna, W. M., Rüschoff, J., Bilous, M., Coudry, R. A., Dowsett, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.103 · Cited by 281
Self-citationGianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., Persons, D. L., Tubbs, R. R., & Hammond, M. E. H. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.611 · Cited by 239
Self-citationIgnatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., Stathopoulos, E. N., Stathopoulou, A., Lianidou, E., Chlouverakis, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7762 · Cited by 237
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Perez, E. A., Reinholz, M. M., Hillman, D. W., Tenner, K. S., Schroeder, M. J., Davidson, N. E., Martino, S., Sledge, G. W., Harris, L. N., Gralow, J. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2154 · Cited by 233
Self-citationDelay to formalin fixation effect on breast biomarkers
Khoury, T., Sait, S., Hwang, H., Chandrasekhar, R., Wilding, G., Tan, D., & Kulkarni, S. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.117 · Cited by 230
(2008) · Cited by 225
Histopathologic variables predict Oncotype DX™ Recurrence Score
Flanagan, M. B., Dabbs, D. J., Brufsky, A. M., Beriwal, S., & Bhargava, R. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.54 · Cited by 222
Marchiò, C., Lambros, M. B., Gugliotta, P., Di Cantogno, L. V., Botta, C., Pasini, B., Tan, D. S., Mackay, A., Fenwick, K., Tamber, N., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2574 · Cited by 202
Russell, S. D., Blackwell, K. L., Lawrence, J., Pippen, J. E., Roe, M. T., Wood, F., Paton, V., Holmgren, E., & Mahaffey, K. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6950 · Cited by 200
Aitken, S. J., Thomas, J. S., Langdon, S. P., Harrison, D. J., & Faratian, D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp427 · Cited by 188
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7939 · Cited by 180
Self-citationAmir, E., Clemons, M., Purdie, C. A., Miller, N., Quinlan, P., Geddie, W., Coleman, R. E., Freedman, O. C., Jordan, L. B., & Thompson, A. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.006 · Cited by 176
HER-2/neu expression in primary and metastatic breast cancer
Lower, E. E., Glass, E., Blau, R., & Harman, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9931-6 · Cited by 171
Press, M. F., Finn, R. S., Cameron, D., Di Leo, A., Geyer, C. E., Villalobos, I. E., Santiago, A., Guzman, R., Gasparyan, A., Ma, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1056 · Cited by 171
Self-citationGuarneri, V., Giovannelli, S., Ficarra, G., Bettelli, S. R., Maiorana, A., Piacentini, F., Barbieri, E., Dieci, M. V., D’Amico, R., Jovic, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0048 · Cited by 150
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
Bempt, I. V., Loo, P. V., Drijkoningen, M., Neven, P., Smeets, A., Christiaens, M.-R., Paridaens, R., & Wolf‐Peeters, C. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4296 · Cited by 146
Yeh, I., Martin, M. A., Robetorye, R. S., Bolla, A. R., McCaskill, C., Shah, R., Gorre, M. E., Mohammed, M. S., & Gunn, S. R. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.78 · Cited by 144
Standardization of HER2 testing: results of an international proficiency-testing ring study
Dowsett, M., Hanna, W. M., Kockx, M. M., Penault-Llorca, F. M., Rüschoff, J., Gutjahr, T., Habben, K., & van de Vijver, M. J. (2007) · Modern Pathology · doi:10.1038/modpathol.3800774 · Cited by 134
Self-citationHER2gene status in primary breast cancers and matched distant metastases
Tapia, C., Savic, S., Wagner, U., Schönegg, R., Novotny, H., Grilli, B., Herzog, M., Barascud, A., Zlobec, I., Cathomas, G., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1676 · Cited by 133
Hammond, M. E., Hayes, D. F., & Wolff, A. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2245 · Cited by 128
Self-citationBaehner, F. L., Achacoso, N. S., Maddala, T., Shak, S., Quesenberry, C. P., Goldstein, L. C., Gown, A. M., & Habel, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8211 · Cited by 128
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Wilking, U., Karlsson, E., Skoog, L. K., Hatschek, T., Lidbrink, E. K., Elmberger, G., Johansson, H., Lindström, L. S., & Bergh, J. C. S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1029-2 · Cited by 122
Hanna, W. M., & Kwok, K. (2006) · Modern Pathology · doi:10.1038/modpathol.3800555 · Cited by 119
Self-citationAutomated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer
Masmoudi, H., Hewitt, S. M., Petrick, N., Myers, K. J., & Gavrielides, M. A. (2009) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2009.2012901 · Cited by 119
Tse, C. H., Hwang, H. C., Goldstein, L. C., Kandalaft, P. L., Wiley, J. C., Kussick, S. J., & Gown, A. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0107 · Cited by 119
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
Gilcrease, M. Z., Woodward, W. A., Nicolas, M. M., Corley, L. J., Fuller, G. N., Esteva, F. J., Tucker, S. L., & Buchholz, T. A. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819437f9 · Cited by 115
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Middleton, L. P., Price, K. M., Puig, P., Heydon, L. J., Tarco, E., Sneige, N., Barr, K., & Deavers, M. T. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.5.775 · Cited by 108
Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers
Arber, D. A. (2002) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200206000-00015 · Cited by 108
Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial
Sparano, J. A., Wang, Μ., Zhao, F., Stearns, V., Martino, S., Ligibel, J. A., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr543 · Cited by 108
Self-citationConcordance Between Central and Local Laboratory HER2 Testing from a Community-Based Clinical Study
Reddy, J. C., Reimann, J. D., Anderson, S. M., & Klein, P. M. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.025 · Cited by 107
HeterogeneousHER2Gene Amplification
Bartlett, A. I., Starcyznski, J., Robson, T., MacLellan, A., Campbell, F., van de Velde, C. J. �., Hasenburg, A., Markopoulos, C. J., Seynaeve, C., Rea, D. W., et al. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp0en6aqmwetzz · Cited by 104
Self-citationRoepman, P., Horlings, H. M., Krijgsman, O., Kok, M., Bueno-de-Mesquita, J. M., Bender, R. A., Linn, S. C., Glas, A. M., & van de Vijver, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0449 · Cited by 99
Hanley, K. Z., Birdsong, G. G., Cohen, C., & Siddiqui, M. T. (2009) · Cancer Cytopathology · doi:10.1002/cncy.20034 · Cited by 88
Perez, E. A., Press, M. F., Dueck, A. C., Jenkins, R. B., Kim, C., Chen, B., Villalobos, I. E., Paik, S., Buyse, M. E., Wiktor, A. E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2444-y · Cited by 83
Self-citationRacial and Ethnic Disparities in Health Care
Etchason, J., Armour, B., Ofili, E., Rust, G. S., Mayberry, R., Sanders, L., & Pitts, M. M. (2001) · JAMA · doi:10.1001/jama.285.7.883-a · Cited by 78
Perez, E. A., Dueck, A. C., McCullough, A. E., Reinholz, M. M., Tenner, K., Davidson, N. E., Gralow, J. R., Harris, L. N., Kutteh, L. A., Hillman, D. W., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr490 · Cited by 78
Self-citationAge/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes
Lund, M., Butler, E. N., Hair, B. Y., Ward, K. C., Andrews, J. H., Oprea-Ilies, G. M., Bayakly, A., O'Regan, R., Vertino, P., & Eley, J. (2010) · Cancer · doi:10.1002/cncr.25016 · Cited by 76
Chang, M. C., Malowany, J. I., Mazurkiewicz, J., & Wood, M. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.206 · Cited by 74
García‐Caballero, T., Grabau, D. A., Green, A. R., Gregory, J., Schad, A., Kohlwes, E., Ellis, I. O., Watts, S., & Mollerup, J. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03503.x · Cited by 73
Breast core needle biopsy: issues and controversies
Bilous, M. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.34 · Cited by 73
Self-citationSáez, A., Andreu, F. J., Seguí, M. Á., Baré, M., Fernández, S., Dinarès, C., & Rey, M. (2005) · The Breast · doi:10.1016/j.breast.2005.09.008 · Cited by 70
Dobson, L. F., Conway, C. M., Hanley, A., Johnson, A., Costello, S., O’Grady, A., Connolly, Y., Magee, H. M., O’Shea, D. G., Jeffers, M., et al. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03577.x · Cited by 69
Bartlett, J. M. S., Ellis, I. O., Dowsett, M., Mallon, E., Cameron, D., Johnston, S. R. D., Hall, E., A’Hern, R., Peckitt, C., Bliss, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0973 · Cited by 67
Self-citationPowell, W. C., Hicks, D. G., Prescott, N. L., Tarr, S. M., Laniauskas, S., Williams, T., Short, S., Pettay, J., Nagle, R. B., Dabbs, D. J., et al. (2007) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31802ced25 · Cited by 65
Self-citationQuantitative PCR and HER2 Testing in Breast Cancer
Barberis, M. C. P., Pellegrini, C., Cannone, M., Arizzi, C., Coggi, G., & Bòsari, S. (2008) · American Journal of Clinical Pathology · doi:10.1309/1akqdq057pqt9akx · Cited by 64
Skaland, I., Øvestad, I. T., Janssen, E. A. M., Kłos, J., Kjellevold, K. H., Helliesen, T., & Baak, J. P. A. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.046763 · Cited by 62
Hall, B. H., Ianosi-Irimie, M., Javidian, P., Chen, W., Ganesan, S., & Foran, D. J. (2008) · BMC Medical Imaging · doi:10.1186/1471-2342-8-11 · Cited by 52
Chivukula, M., Bhargava, R., Brufsky, A., Surti, U., & Dabbs, D. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801021 · Cited by 52
Chibon, F., de Mascarel, I., Sierankowski, G., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.195 · Cited by 52
Vocaturo, A., Novelli, F., Benevolo, M., Piperno, G., Marandino, F., Cianciulli, A. M., Merola, R., Donnorso, R. P., Sperduti, I., Buglioni, S., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-8-878 · Cited by 51
Carbone, A., Botti, G., Gloghini, A., Simone, G., Truini, M., Curcio, M. P., Gasparini, P., Mangia, A., Perin, T., Salvi, S., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080052 · Cited by 46
Bergqvist, J., Öhd, J., Smeds, J., Klaar, S., Isola, J. J., Nordgren, H., Elmberger, G., Hellborg, H., Bjöhle, J., Borg, A.-L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm059 · Cited by 39
External Quality Assurance of HER2 FISH and ISH Testing
Bartlett, J. M. S., Ibrahim, M., Jasani, B., Morgan, J. M., Ellis, I. O., Kay, E. W., Connolly, Y., Campbell, F., O’Grady, A., Barnett, S., et al. (2008) · American Journal of Clinical Pathology · doi:10.1309/ajcpln78zqxemnma · Cited by 37
Self-citationVani, K., Sompuram, S. R., Fitzgibbons, P. L., & Bogen, S. A. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-211-nhptru · Cited by 34
Self-citationSłodkowska, J., Filas, V., Buszkiewicz, E., et al. (2010) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0015-1 · Cited by 33
Bates, M. P., Sperinde, J., Köstler, W. J., Ali, S. M., Leitzel, K., Fuchs, E., Paquet, A. C., Lie, Y., Sherwood, T., Horvat, R., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq706 · Cited by 30
Shah, S., Wang, Y., Tull, J., & Zhang, S. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31817c1af8 · Cited by 26
Hammond, E. H., Wolff, A. C., Hayes, D. F., & Schwartz, J. N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0366 · Cited by 13
Self-citationMonego, G., Arena, V., Maggiano, N., et al. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601128934 · Cited by 12
Francz, M., Égervári, K., Kardos, L., Tóth, J., Nemes, Z., Szántó, J., & Szöllősi, Z. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.066852 · Cited by 8
Cited by
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Metadata
- Authors
- Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Mangu, P. B., Paik, S., Perez, E. A., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., & Hayes, D. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-01
- Volume
- 31
- Issue
- 31
- Pages
- 3997-4013
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101979288
- Cited by
- 4,030
- References
- 87
- FWCI
- 145.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.